Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
In Vitro, Ex Vivo and In Vivo Methods of Lung...
share announcement

In Vitro, Ex Vivo and In Vivo Methods of Lung Absorption for Inhaled Drugs

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biopharmaceutics".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 1029

Special Issue Editors

Dr. Wenlei Jiang

E-Mail Website
Guest Editor
Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA
Interests: pharmaceutics; pharmacokinetics; bioequivalence; drug delivery; regulatory science
Prof. Dr. Carsten Ehrhardt

E-Mail Website
Guest Editor
School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute (TBSI), Trinity College Dublin, Dublin 2, Ireland
Interests: inhalation biopharmaceutics; lung drug disposition; pulmonary epithelial transport and molecular origins of airways disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Respiratory diseases including asthma, chronic obstructive lung disease, cystic fibrosis and others are among the global leading causes of morbidity and mortality.  Pulmonary drug delivery via inhalation is the preferred administration route for the treatment of such diseases. Most inhaled drugs, excluding muclyotic agents or antibiotics, require to be absorbed into or across the respiratory epithelium to exert pharmacological functions. An improved understanding about the lung absorption for inhaled drugs, i.e., dissolution, permeation, and tissue retention of the drug in the lung is essential to ensure the efficient and successful development of inhalation drugs. This special issue aims to highlight recent advancements in different tools to describe lung absorption process, including In Vitro, Ex Vivo and In Vivo methods, examine clinical relevance of different methods, clarify the scope of their applications, and identify further research needs in this field.

Dr. Wenlei Jiang
Prof. Dr. Carsten Ehrhardt
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pulmonary drug delivery
  • inhalation
  • inhaled drugs
  • lung absorption process
  • tools

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 2786 KiB  
Article
The Pharmacokinetics of CPZEN-45, a Novel Anti-Tuberculosis Drug, in Guinea Pigs
by Lucila Garcia-Contreras, Shumaila Nida Muhammad Hanif, Mariam Ibrahim, Phillip Durham and Anthony J. Hickey
Pharmaceutics 2023, 15(12), 2758; https://doi.org/10.3390/pharmaceutics15122758 - 12 Dec 2023
Viewed by 704
Abstract
CPZEN-45 is a novel compound with activity against drug-susceptible and drug-resistant tuberculosis (TB). The present study was undertaken to determine the best dose and dosing regimen of inhalable CPZEN-45 powders to use in efficacy studies with TB-infected guinea pigs. The disposition of CPZEN-45 [...] Read more.
CPZEN-45 is a novel compound with activity against drug-susceptible and drug-resistant tuberculosis (TB). The present study was undertaken to determine the best dose and dosing regimen of inhalable CPZEN-45 powders to use in efficacy studies with TB-infected guinea pigs. The disposition of CPZEN-45 after intravenous, subcutaneous (SC), and direct pulmonary administration (INS) was first determined to obtain their basal pharmacokinetic (PK) parameters. Then, the disposition of CPZEN-45 powders after passive inhalation using consecutive and sequential doses was evaluated. Plasma concentration versus time curves and PK parameters indicated that the absorption of CPZEN-45 after INS was faster than after SC administration (Ka = 12.94 ± 5.66 h−1 and 1.23 ± 0.55 h−1, respectively), had a longer half-life (2.06 ± 1.01 h versus 0.76 ± 0.22 h) and had higher bioavailability (67.78% and 47.73%, respectively). The plasma concentration versus time profiles and the lung tissue concentration at the end of the study period were not proportional to the dose size after one, two, and three consecutive passive inhalation doses. Three sequential passive inhalation doses maintained therapeutic concentration levels in plasma and lung tissue for a longer time than three consecutive doses (10 h vs. 3 h, respectively). Future studies to evaluate the efficacy of inhaled CPZEN-45 powders should employ sequential doses of the powder, with one nominal dose administered to animals three times per day. Full article
(This article belongs to the Special Issue In Vitro, Ex Vivo and In Vivo Methods of Lung Absorption for Inhaled Drugs)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop